BioCentury
ARTICLE | Finance

Targeting pharma

Why Second Genome courted pharma VCs in its series B

April 25, 2016 7:00 AM UTC

Second Genome Inc. was looking for more than money in the $42.6 million series B round announced last week. The microbiome company also wanted to tap into pharma expertise that can help it develop a portfolio of small and large molecule therapeutics in indications where it does not have internal expertise.

"As we went out for this financing we really targeted the pharma venture community. There's expertise in those organizations that can help," said CEO Peter DiLaura. "We want to make sure that we have access to those organizations when we go into areas of new clinical relevance where we don't have internal expertise."...